Evolution of management of gout: A comparison of recent guidelines

Current Opinion in Rheumatology

Volumn 27, Issue 2, 2015, Pages 139-146

  Khanna, Puja P ^a   Fitzgerald, John ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute; advances in gout; chronic; imaging

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; ANTIINFLAMMATORY AGENT; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DIURETIC AGENT; FEBUXOSTAT; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PEGLOTICASE; PROBENECID; STEROID; TRIAMCINOLONE ACETONIDE; URIC ACID; URICOSURIC AGENT; XANTHINE OXIDASE INHIBITOR;

COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DIURETIC THERAPY; ECHOGRAPHY; EPIDEMIOLOGY; GOUT; HUMAN; HYPERURICEMIA; LIFESTYLE MODIFICATION; MEDICATION COMPLIANCE; MONOTHERAPY; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STEROID THERAPY; TREATMENT DURATION; URIC ACID BLOOD LEVEL; ACUTE DISEASE; CHRONIC DISEASE; COMPARATIVE STUDY;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; MEDICATION ADHERENCE; PRACTICE GUIDELINES AS TOPIC;

EID: 84922415052     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000154     Document Type: Review

References (41)

1. Juraschek SP, Kovell LC, Miller ER 3rd, Gelber AC. Gout, urate lowering therapy and uric acid levels among US adults. Arthritis Care Res (Hoboken) 2014. [Epub ahead of print]
2. Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. Arthritis Rheum 2011; 63:3136-3141.
3. Singh JA. Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study. Arthritis Res Ther 2014; 16:R82.
4. Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46:1372-1374.
5. Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64:1431-1446.
6. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014; 73:328-335.
7. Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1312-1324.
8. Zhang W, Doherty M, Pascual E, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65:1301-1311.
9. Rees F, Hui M, Doherty M. Optimizing current treatment of gout. Nat Rev Rheumatol 2014; 10:271-283.
10. Singh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007; 57:822-829.
11. Wall GC, Koenigsfeld CF, Hegge KA, Bottenberg MM. Adherence to treatment guidelines in two primary care populations with gout. Rheumatol Int 2010; 30:749-753.
12. De Vera MA, Marcotte G, Rai S, et al. Medication adherence in gout: a systematic review. Arthritis Care Res (Hoboken) 2014; 66:1551-1559.
13. Nuki G. An appraisal of the 2012 American College of Rheumatology Guidelines for the Management of Gout. Curr Opin Rheumatol 2014; 26:152-161.
14. Khanna PP, Gladue HS, Singh MK, et al. Treatment of acute gout: a systematic review. Semin Arthritis Rheum 2014; 44:31-38.
15. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010; 182:E839-E842.
16. Khanna D, Khanna PP, Fitzgerald JD, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64:1447-1461.
17. So A, Revaz DT, Tschopp SJ. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 2007; 9:R28.
18. Kydd AS, Seth R, Buchbinder R, et al. Urate-lowering therapy for the management of gout: a summary of 2 Cochrane reviews. J Rheumatol Suppl 2014; 92:33-41.
19. Kydd AS, Seth R, Buchbinder R, et al. Uricosuric medications for chronic gout. Cochrane Database Syst Rev 2014; 11:CD010457.
20. Becker MA, Baraf HS, Yood RA, et al. Long-term safety of pegloticase in chronic gout refractory to conventional treatment. Ann Rheum Dis 2013; 72:1469-1474.
21. Sundy JS, Baraf HS, Yood RA, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306:711-720.
22. Khanna P, Bae SM, FitzGerald S, et al. Oral urate lowering therapies in chronic gout: a systematic review and meta-analysis. Arthritis Rheum 2011; 63 (Suppl):S405.
23. Seth R, Kydd AS, Buchbinder R, et al. Allopurinol for chronic gout. Cochrane Database Syst Rev 2014; 10:CD006077.
24. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12:R63.
25. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 2009; 36:1273-1282.
26. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004; 31:2429-2432.
27. Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974; 17:609-614.
28. Schlesinger N, Mysler E, Lin HY, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011; 70:1264-1271.
29. Ottaviani S, Allard A, Bardin T, Richette P. An exploratory ultrasound study of early gout. Clin Exp Rheumatol 2011; 29:816-821.
30. Thiele RG, Schlesinger N. Diagnosis of gout by ultrasound. Rheumatology (Oxford) 2007; 46:1116-1121.
31. Thiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 2010; 30:495-503.
32. Perez-Ruiz F, Martin I, Canteli B. Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 2007; 34:1888-1893.
33. Lamers-Karnebeek FB, Van Riel PL, Jansen TL. Additive value for ultrasonographic signal in a screening algorithmfor patients presenting with acutemono-/oligoarthritis in whom gout is suspected. Clin Rheumatol 2014; 33:555-559.
34. Huppertz A, Hermann KG, Diekhoff T, et al. Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int 2014; 34:763-771.
35. Kuo-Lung Lai Y-MC. Role of ultrasonography in diagnosing gouty arthritis. J Med Ultrasound 2011; 19:7-13.
36. Chowalloor PV, Keen HI. A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis 2013; 72:638-645.
37. Naredo E, Uson J, Jimenez-Palop M, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 2014; 73:1522-1528.
38. Choi HK, Al-Arfaj AM, Eftekhari A, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009; 68:1609-1612.
39. Choi HK, Burns LC, Shojania K, et al. Dual energy CT in gout: a prospective validation study. Ann Rheum Dis 2012; 71:1466-1471.
40. Ogdie A, Taylor WJ, Weatherall M, et al. Imaging modalities for the classification of gout: systematic literature review and meta-analysis. Ann Rheum Dis 2014. [Epub ahead of print]
41. Bongartz T, Glazebrook KN, Kavros SJ, et al. Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 2014. [Epub ahead of print]